Inserire di nuova l’introduzione
SNCTP000001339 | NCT02467582

SAKK 41/13-Aspirin. Ergänzende Aspirin-Behandlung bei Dickdarmkrebs. Eine randomisierte, doppelblinde, Placebo-kontrollierte Phase III Studie.

Base di dati: BASEC (Importata da 27.01.2022), WHO (Importata da 18.01.2022)
Cambiato: 20.12.2020
Categoria di malattie: Altro cancro

Descrizione riassuntiva della sperimentazione (Fonte di dati: BASEC)

Die Studie untersucht bei Patienten mit operiertem Dickdarmkrebs und vorhandener PIK3CA-Mutation den Einfluss von Aspirin auf die Wahrscheinlichkeit eines Rückfalls der Tumorerkrankung. Etwa 17% der Patienten mit Dickdarmkrebs weisen eine solche Genmutation im Tumorgewebe auf. Das PIK3CA spielt eine wichtige Rolle beim Wachstum und Überleben der Krebszellen. Aspirin enthält den Wirkstoff Acetylsalicylsäure, welcher den Einfluss von PIK3CA auf die Krebszellen möglicherweise verändern kann. Um diesen Einfluss zu untersuchen, wird Aspirin gegenüber Placebo verglichen.

Malattie studiate (Fonte di dati: BASEC)

Patienten mit operiertem Dickdarmkrebs

Health conditions (Fonte di dati: WHO)

Colon Cancer

Malattia rara (Fonte di dati: BASEC)


Interventi esaminati (p. es. medicamento, terapia, campagna) (Fonte di dati: BASEC)

Aspirin 100 mg oder Placebo werden täglich während 3 Jahren verabreicht

Interventions (Fonte di dati: WHO)

Drug: Aspirin;Drug: Placebo

Criteri per la partecipazione alla sperimentazione (Fonte di dati: BASEC)

- Histologisch bewiesenes Kolonkarzinom.
- Stadium II (pT3/T4 N0 cM0) oder Stadium III (pTx pN+ cM0).
- Aktivierende PIK3CA Mutation in den Exon 9 oder 20.

Criteri di esclusione (Fonte di dati: BASEC)

- Patienten mit Rektumkarzinom.
- Schwere und unkontrollierte kardiovaskuläre Erkrankung.

Inclusion/Exclusion Criteria (Fonte di dati: WHO)

Inclusion Criteria:

- Written informed consent according to ICH/GCP regulations before inclusion and prior
to any trial-related investigations.

- Histologically confirmed diagnosis of adenocarcinoma of the colon.

- Stage II (pT3/T4 N0 cM0) or stage III (pTx pN+ cM0) colon cancer.

- Availability of cancer tissue for central molecular testing.

- Presence of predefined, activating PIK3CA mutation in exons 9 or 20 (centrally

- Complete resection of the primary tumor (R0) within 14 weeks maximum before

- WHO performance status 0-2.

- Age between 18-80 years.

- Adequate hematological values: hemoglobin = 80 g/L, platelets = 50 x 109/L.

- Adequate hepatic function: total bilirubin =1.5xULN, AST =2.5xULN, ALT =2.5xULN, AP

- Calculated creatinine clearance > 30 mL/min, according to the formula of

- Women with child-bearing potential are using effective contraception, are not pregnant
or lactating and agree not to become pregnant during trial treatment. A negative
pregnancy test before inclusion (within 7 days) into the trial is required for all
women with child-bearing potential.

Exclusion Criteria:

- Previous or concomitant malignancy within 3 years of registration, except for
adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer.

- Multiple adenocarcinomas of the colon.

- Rectal cancer (defined as distance from anal verge to proximal/oral tumor edge =15

- Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or
IV, unstable angina pectoris, history of myocardial infarction) within three months
prior to registration.

- Systemic rheumatic diseases or degenerative disorders affecting the musculoskeletal
system with a relevant risk of requiring treatment with NSAIDs in the future.

- Comorbidities that require regular (i.e. more than 3x per month, any dose) intake of
acetylsalicylic acid or other NSAIDs or COX-2 inhibitors.

- Clinically relevant upper gastro-intestinal bleeding within 12 months prior to

- Presence of any bleeding disorder that is an absolute contraindication to the use of

- General tendency to hypersensitivity and history of asthma triggered by salicylates or
substances with a similar mechanism of action, and non-steroidal anti-inflammatory
drugs in particular

- Any serious underlying medical condition, at the judgment of the investigator, which
could impair the ability of the patient to participate in the trial (e.g. uncontrolled
infection, active autoimmune disease, uncontrolled diabetes).

- Concurrent treatment with other experimental drugs or treatment in an interventional
clinical trial within 30 days prior to trial entry. Concomitant use of adjuvant
chemotherapy for stage III and high risk stage II colon cancer according to
international treatment guidelines is allowed (chemotherapy regimens include
intravenous 5-fluorouracil or oral capecitabine either alone or in combination with
intravenous oxaliplatin).

- Psychiatric disorder precluding understanding of trial information, giving informed
consent or interfering with compliance for oral drug intake.

- Any familial, sociological or geographical condition potentially hampering proper
staging and compliance with the trial protocol.

- Known or suspected hypersensitivity to any component of the trial drug or any agent
given in association with this trial.

- Known galactose-1-phosphate uridyl transferase deficiency, UDP galactose 4 epimerase
deficiency, galactokinase deficiency, orFanconi-Bickel syndrome, congenital lactase
deficiency,or glucose-galactose malabsorption (due to the lactose-containing placebo).

- Any concomitant drugs contraindicated for use with the trial drug according to the
approved product information.

Altri dati sulla sperimentazione nel registro primario dell’OMS

Altri dati sulla sperimentazione dalla banca dati dell’OMS (ICTRP)

Altre informazioni sulla sperimentazione

Data di registrazione della sperimentazione


Inserimento del primo partecipante


Stato di reclutamento


Titolo scientifico (Fonte di dati: WHO)

Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial

Tipo di sperimentazione (Fonte di dati: WHO)


Disegno della sperimentazione (Fonte di dati: WHO)

Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).

Fase (Fonte di dati: WHO)

Phase 3

Punti finali primari (Fonte di dati: WHO)

Disease-free survival (DFS)

Punti finali secondari (Fonte di dati: WHO)

Adverse events (AEs);Cancer-specific survival (CSS);Overall survival (OS);Time to recurrence (TTR)

Contatto per informazioni (Fonte di dati: WHO)

Please refer to primary and secondary sponsors

Risultati della sperimentazione (Fonte di dati: WHO)

Sintesi dei risultati

ancora nessuna informazione disponibile

Collegamento ai risultati nel registro primario

ancora nessuna informazione disponibile

Informazioni sulla disponibilità dei dati dei singoli partecipanti


Siti di esecuzione della sperimentazione

Siti di esecuzione in Svizzera (Fonte di dati: BASEC)

Aarau, Baden, Basilea, Bellinzona, Biel, Chur, Friburgo, Ginevra, Liestal, Losanna, Luzern, Olten, San Gallo, Sion, Thun, Winterthur, Zurigo

Paesi di esecuzione (Fonte di dati: WHO)

Belgium, Germany, Hungary, Switzerland

Contatto per maggiori informazioni sulla sperimentazione

Dati della persona di contatto in Svizzera (Fonte di dati: BASEC)

Rothgiesser Karin
031 508 41 57

Contatto per informazioni generali (Fonte di dati: WHO)

Ulrich Güller, Prof;Karin Rotgiesser, PhD
Cantonal Hospital of St. Gallen
+41 31 389 91 91

Contatto per informazioni scientifiche (Fonte di dati: WHO)

Ulrich Güller, Prof;Karin Rotgiesser, PhD
Cantonal Hospital of St. Gallen
+41 31 389 91 91

Responsabile della sperimentazione

Sponsor principale (Fonte di dati: WHO)

Swiss Group for Clinical Cancer Research

Altri sponsor (Fonte di dati: WHO)

European Organisation for Research and Treatment of Cancer - EORTC;Central European Society for Anticancer Drug Research

Autorizzazione da parte della commissione d’etica (Fonte di dati: BASEC)

Nome della commissione d’etica che rilascia l’autorizzazione (nel caso di studi multicentrici solo la commissione direttiva)

Commissione d'etica San Gallo

Altri numeri di identificazione delle sperimentazioni

Secondary ID (Fonte di dati: WHO)

SAKK 41/13 - Aspirin